Patents-Review.com
ClassID:

109901 ⎘

C12N2710/16662 - CPC Classification

Classification description:

dsDNA viruses; Details; Herpesviridae; Simplexvirus, e.g. human herpesvirus 1, 2; Methods of inactivation or attenuation by genetic engineering

Recent Application in this class:
#1
20260115327
2026-04-30

Viral Vectors for Cancer Therapy

 #2
20260097135
2026-04-09

MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (oHSV) AND METHODS OF USE THEREOF

 #3
20250302945
2025-10-02

METHOD FOR TREATING GLIOMA WITH OHSV2

 #4
20250161384
2025-05-22

TRANSCRIPTIONAL AND TRANSLATIONAL DUAL REGULATED ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS

 #5
20250049867
2025-02-13

ENGINEERED ONCOLYTIC HERPESVIRUSES

 #6
20250001004
2025-01-02

Methods and Compositions for Treating Conditions Involving the Eye

 #7
20240398994
2024-12-05

Viral Vectors for Cancer Therapy

 #8
20240342308
2024-10-17

Methods and Compositions for Treating Conditions Involving the Eye

 #9
20240216533
2024-07-04

HERPES SIMPLEX VIRUS AND USE THEREOF

 #10
20240189420
2024-06-13

PSEUDORABIES VIRUS VACCINE

 #11
20240158809
2024-05-16

High-transducing HSV vectors

 #12
20240150787
2024-05-09

ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITY

 #13
20230338583
2023-10-26

VIRAL VECTORS FOR CANCER THERAPY

 #14
20230270846
2023-08-31

Replication-competent controlled alpha-herpesvirus vectors and uses therefore

 #15
20230270833
2023-08-31

Modulation of replicative fitness by deoptimization of synonymous codons

 #16
20230241251
2023-08-03

Viral vectors for cancer therapy

 #17
20230227549
2023-07-20

ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

 #18
20230115116
2023-04-13

ONCOLYTIC VIRAL VECTORS AND USES THEREOF

 #19
20220323613
2022-10-13

Viral vectors for cancer therapy

 #20
20220307052
2022-09-29

RECOMBINANT HERPESVIRALES VECTOR

 #21
20220241401
2022-08-04

VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS

 #22
20210261649
2021-08-26

COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY

 #23
20210138007
2021-05-13

Oncolytic HSV vector

 #24
20210107946
2021-04-15

Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens

 #25
20200376114
2020-12-03

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #26
20200345836
2020-11-05

Vaccines against genital herpes simplex infections

 #27
20200268865
2020-08-27

Modulation of replicative fitness by deoptimization of synonymous codons

 #28
20200206314
2020-07-02

HSV vectors for delivery of NT3 and treatment of CIPN

 #29
20200199618
2020-06-25

High-transducing HSV vectors

 #30
20200147156
2020-05-14

Oncolytic viral vectors and uses thereof

 #31
20200023058
2020-01-23

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #32
20190359990
2019-11-28

Viral synthetic nucleic acid sequences and use thereof

 #33
20190262410
2019-08-29

Oncolytic HSV vector

 #34
20190240321
2019-08-08

Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #35
20190111127
2019-04-18

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #36
20190091327
2019-03-28

Vaccines against genital herpes simplex infections

 #37
20180339004
2018-11-29

Oncolytic viral vectors and uses thereof

 #38
20180312872
2018-11-01

RECOMBINANT VIRUS PRODUCTION USING MAMMALIAN CELLS IN SUSPENSION

 #39
20180264098
2018-09-20

Modulation of replicative fitness by deoptimization of synonymous codons

 #40
20170354727
2017-12-14

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS

 #41
20170290908
2017-10-12

Viral vectors and their use in therapeutic methods

 #42
20170274025
2017-09-28

Oncolytic HSV vector

 #43
20170202952
2017-07-20

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #44
20170035819
2017-02-09

Oncolytic HSV vector

 #45
20160250267
2016-09-01

Oncolytic HSV vector

 #46
20160158343
2016-06-09

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

 #47
20160000903
2016-01-07

Neuroattenuated herpes simplex virus

 #48
20140363469
2014-12-11

VIRAL ATTENUATION AND VACCINE PRODUCTION

 #49
20130244331
2013-09-19

Recombinant virus production using mammalian cells in suspension

 #50
20130034586
2013-02-07

Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response

 #51
20130028925
2013-01-31

HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF

 #52
20120263752
2012-10-18

Herpes simplex virus vaccines

 #53
20110274661
2011-11-10

Attentuated Herpesvirus Encoding a Mek Pathway Polypeptide

 #54
20110256176
2011-10-20

Herpes simplex virus combined subunit vaccines and methods of use thereof

 #55
20110236415
2011-09-29

Virulent oncolytic herpes simplex virus strains engineered to counter the innate host response

 #56
20110229971
2011-09-22

RECOMBINANT VIRUS PRODUCTION USING MAMMALIAN CELLS IN SUSPENSION

 #57
20110070262
2011-03-24

Viral vectors and their use in therapeutic methods

 #58
20100297085
2010-11-25

Synthetic herpes simplex viruses type-1 for treatment of cancers

 #59
20090148467
2009-06-11

Herpes simplex virus combined subunit vaccines and methods of use thereof

 #60
20090098162
2009-04-16

Herpes simplex virus combined subunit vaccines and methods of use thereof

 #61
20090068215
2009-03-12

Herpes simplex virus mutant ICP0 protein

 #62
20080118530
2008-05-22

Modulation of replicative fitness by deoptimization of synonymous codons

 #63
20070280963
2007-12-06

Method for Producing Non-Pathogenic Helper Virus-Free Preparations of Herpes Virus Amplicon Vectors, the Helper Virus and the Cells Used in this Method, the Corresponding Generic Tools, as Well as the Applications of These Non-Pathogenic Amplicon Vectors

 #64
20060204477
2006-09-14

Helper virus-free herpesvirus amplicon particles and uses thereof

 #65
20060039894
2006-02-23

Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response

 #66
20050118192
2005-06-02

Viral preparations, vectors, immunogens, and vaccines